Oxford BioMedica (LSE: OXB) is a biopharmaceutical company based in Oxford, UK, that specialises in developing gene and cell therapies. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. As of this post, Oxford BioMedica Share Price is at 428.50 GBX.
Oxford BioMedica is a biopharmaceutical company founded in 1995 and based in Oxford, UK. The company specialises in the development of gene and cell therapies and has been at the forefront of this field for over two decades.
In its early years, Oxford BioMedica focused on developing gene-based treatments for cancer and HIV. The company’s research and development efforts led to the creation of its LentiVector platform technology, which enables the delivery of therapeutic genes into a patient’s cells.
Over time, Oxford BioMedica expanded its focus to include other therapeutic areas, such as ophthalmology and neurodegenerative diseases. In addition, the company has partnered with several pharmaceutical and biotech companies to develop and commercialise its therapies.
One of Oxford BioMedica’s key milestones was approving its gene therapy Strimvelis in 2016. Strimvelis is a treatment for a rare immunodeficiency disorder known as severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and was the first gene therapy to receive regulatory approval in Europe.
Today, Oxford BioMedica continues to be a leader in gene and cell therapy and is working on developing new treatments for various diseases, including cancer, ocular diseases, and neurological disorders. The company also focuses on expanding its manufacturing capabilities to meet the growing gene and cell therapies demand.
The gene and cell therapy field is expected to increase in the coming years as new treatments are developed and approved. Oxford BioMedica Share Price is one of the leading companies in this field, with a strong track record of developing innovative gene and cell therapies.
Oxford BioMedica Share Price has a diversified pipeline of therapies in various stages of development, targeting a range of diseases, including cancer, ocular diseases, and neurological disorders. This diversification can help mitigate risk, as the success of one therapy can offset any setbacks in others.
Oxford BioMedica has formed partnerships with several pharmaceutical and biotech companies, which can provide a source of revenue and additional resources for developing and commercialising its therapies.
Oxford BioMedica’s LentiVector platform technology is an established and validated gene delivery system used in multiple clinical trials. This technology is expected to have broad applications across many therapeutic areas.
- Novartis AG. A Swiss multinational pharmaceutical company is focusing strongly on cell and gene therapy. Novartis has developed several successful gene therapies, including Kymriah and Zolgensma.
- bluebird bio. A US-based biotech company that specialises in gene therapies for genetic diseases. The company has developed the gene therapy Zynteglo for transfusion-dependent β-thalassemia.
- Spark Therapeutics. A US-based biotech company that has developed the gene therapy Luxturna for inherited retinal diseases. The company was acquired by Roche in 2019.
- uniQure. A Dutch biotech company that focuses on gene therapies for rare genetic diseases. The company has developed the gene therapy Glybera for lipoprotein lipase deficiency.
- GenSight Biologics. A French biotech company that focuses on developing gene therapies for inherited retinal diseases. The company has developed the gene therapy LUMEVOQ for Leber hereditary optic neuropathy.
